BeiGene
BGNE
#900
Rank
HK$175.45 B
Marketcap
HK$1,598
Share price
-0.65%
Change (1 day)
2.75%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Market capitalization of BeiGene (BGNE)

Market cap: HK$175.45 Billion

As of November 2024 BeiGene has a market cap of HK$175.45 Billion. This makes BeiGene the world's 900th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of BeiGene from 2016 to 2024

End of year Market Cap

Year Marketcap Change
2024HK$175.45 B13.36%
2023HK$154.78 B-15.56%
2022HK$183.31 B-14.48%
2021HK$214.35 B15.06%
2020HK$186.29 B132.49%
2019HK$80.12 B22.77%
2018HK$65.26 B87.71%
2017HK$34.77 B272.22%
2016HK$9.34 B

End of Day market cap according to different sources

On Nov 9th, 2024 the market cap of BeiGene was reported to be:

HK$178.77 Billion
by Yahoo Finance info icon info icon
HK$175.45 Billion
by CompaniesMarketCap info icon info icon
HK$169.53 Billion
by Nasdaq info icon info icon

Market capitalization for similar companies or competitors

Name Marketcap Market cap differencediff. Country
HK$0.16 B-99.91%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$8.17 B-95.34%๐Ÿ‡บ๐Ÿ‡ธ USA